Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
Completed · Phase 2 · NCT03340675
Conditions: Duchenne Muscular Dystrophy Cardiomyopathy, Cardiomyopathy, Dilated
At a glance
- Research payments reported, 2025
- $66,609
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 46
About the trial
- Sponsor
- Cumberland Pharmaceuticals (with Vanderbilt University Medical Center)
- Tested
- Ifetroban (drug), Placebo (drug)
- Dates
- Started 2020-10-19; completion 2026-01-23
- Results posted
- Yes
Duchenne muscular dystrophy (DMD) is a devastating X-linked disease which leads to loss of ambulation between ages 7 and 13, respiratory failure and cardiomyopathy (CM) at any age, and inevitably premature death of affected young men in their late twenties. DMD is the most common fatal genetic disorder diagnosed in childhood. It affects approximately 1 in every 3,500 live male births across all races and cultures, and results in 20,000 new cases each year worldwide.Significant advances in respiratory care have unmasked CM as the leading cause of death. As there are yet no specific cardiac treatments to extend life, the current study aims to address this unmet medical need using a new ther…
From ClinicalTrials.gov, last updated 2026-03-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Cumberland Pharmaceuticals, Inc. reported $66,609 in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Markus S. Renno, MD, MPH Pediatric Cardiology · Little Rock, AR
- Katheryn E. Gambetta, MD Pediatric Cardiology · Chicago, IL
- John J. Parent, M.D. Pediatric Cardiology · Indianapolis, IN
- Doris G. Leung, M.D. Neurology · Baltimore, MD
- Craig M. Zaidman, MD Child Neurology · Saint Louis, MO
- Jonathan H. Soslow, MD Pediatric Cardiology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Washington University $30,497
- Hugo W Moser Research Institute at Kennedy Krieger Inc $17,744
- Indiana University $13,272
- Arkansas Children's Hospital, AR $3,699
- Vanderbilt University Medical Center $1,100
- Ann & Robert H Lurie Children's Hospital of Chicago $298
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.